US Patent Application No: 2003/0157,117

Number of patents in Portfolio can not be more than 2000

Novel method for down-regulation of amyloid

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta., said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A.beta. and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
H. LUNDBECK A/SVALBY-COPENHAGEN202

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Degan, Florence Dal Horsholm, DK 5 34
Jensen, Martin Roland Horsholm, DK 12 101
Koefoed, Peter Horsholm, DK 5 70
Nielsen, Klaus Gregorius Horsholm, DK 16 202
Rasmussen, Peter Birk Horsholm, DK 25 178

Cited Art Landscape

Patent Info (Count) # Cites Year
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (3)
* 6,787,523 Prevention and treatment of amyloidogenic disease 76 1998
* 6,761,888 Passive immunization treatment of Alzheimer's disease 93 2000
* 6,787,637 N-Terminal amyloid-.beta. antibodies 79 2000
 
EPIMMUNE INC. (1)
* 5,736,142 Alteration of immune response using pan DR-binding peptides 82 1994
 
NEW YORK UNIVERSITY (2)
* 2002/0077,288 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits 10 2001
* 6,713,450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 49 2001
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
* 2011/0086,036 COMPOSITION COMPRISING VLP AND AMYLOID BETA PEPTIDE 0 2010
 
PROTHENA BIOSCIENCES LIMITED (1)
8,673,593 Antibodies to alpha-synuclein 0 2011
 
The Regents of the University of California (10)
8,697,082 Prevention and treatment of synucleinopathic and amyloidogenic disease 0 2004
8,506,959 Prevention and treatment of synucleinopathic and amyloidogenic disease 4 2005
* 2010/0031,377 Prevention and treatment of synucleinopathic and amyloidogenic disease 1 2005
* 9,034,337 Treatment and delay of outset of synucleinopathic and amyloidogenic disease 0 2007
* 2008/0014,194 Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease 24 2007
8,147,833 Prevention and treatment of synucleinopathic and amyloidogenic disease 6 2008
* 2010/0086,545 Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease 5 2008
8,092,801 Prevention and treatment of synucleinopathic and amyloidogenic disease 6 2008
* 2010/0278,814 Prevention and treatment of synucleinopathic and amyloidogenic disease 2 2008
* 2011/0135,660 PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE 5 2010
 
NOVARTIS AG (2)
8,460,676 Composition comprising VLP and amyloid beta peptide 0 2010
8,617,566 Composition comprising VLP and amyloid beta peptide 0 2013
 
SIEMENS AKTIENGESELLSCHAFT (2)
* 7,850,973 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease 0 2006
* 2009/0098,155 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease 1 2006
 
ABBVIE DEUTSCHLAND GMBH & CO. KG (2)
8,895,004 Method for the treatment of amyloidoses 0 2008
9,176,150 Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof 0 2011
 
ABBVIE INC. (8)
8,691,224 Anti-Aβ globulomer 5F7 antibodies 0 2006
8,497,072 Amyloid-beta globulomer antibodies 0 2006
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies 0 2007
8,987,419 Amyloid-beta binding proteins 0 2011
8,877,190 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2011
9,062,101 Amyloid-beta binding proteins 0 2011
9,359,430 Abeta conformer selective anti-Abeta globulomer monoclonal antibodies 0 2013
9,394,360 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2014
 
PHARMEXA A/S (1)
* 2005/0163,744 Novel method for down-regulation of amyloid 11 2004
 
Intezyne Technologies, Inc. (2)
7,618,944 Encapsulated amyloid-beta peptides 20 2008
* 2008/0274,965 ENCAPSULATED AMYLOID-BETA PEPTIDES 5 2008
 
Curix ApS (1)
* 2007/0172,496 Conjugates of amyloid proteins as vaccines for amyloid-related diseases 2 2005
 
UNIVERSITY OF SOUTH FLORIDA (1)
8,188,046 Amyloid beta peptides and methods of use 0 2007
 
ELAN PHARMACEUTICALS, INC. (1)
* 2009/0035,217 Truncated Fragments of Alpha-Synuclein in Lewy Body Disease 0 2008
 
H. LUNDBECK A/S (5)
7,135,181 Method for down-regulation of amyloid 17 2001
* 2003/0086,938 Novel methods for down-regulation of amyloid 30 2002
* 2009/0092,579 NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID 1 2008
8,871,212 Amyloid-beta polypeptide vaccine 0 2008
* 2010/0047,262 NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID 0 2008
 
GLAXOSMITHKLINE BIOLOGICALS SA (1)
* 2012/0321,694 COMPOSITIONS AND USES 0 2012
* Cited By Examiner